Inotek Stops Development of Trabodenoson after Second Failed Study

August 4, 2017: By Joan McKenna

1 Ophthalmic News

Inotek has discontinued all preclinical and clinical development activities associated with trabodenoson to preserve its cash to pursue other opportunities, the Lexington, Massachusetts, drugmaker announced Aug. 3.

Trabodenoson, in development as a treatment for glaucoma, missed its primary endpoint in separate Phase II and III studies in 2017. It was the only drug candidate in the company’s pipeline.

David Southwell, president and CEO of Inotek, said: “We continue to actively evaluate strategic alternatives to maximize shareholder value and are well-funded with $108.8 million in cash and marketable securities as of the end of the second quarter.”

The company has 19 employees, according to the Boston Business Journal.

The latest study, a Phase II trial, evaluated trabodenoson’s use in combination with Pfizer’s Xalatan (latanoprost) compared with Xalatan alone.

Inotek announced July 7 that the addition of trabodenoson to latanoprost in the Phase II trial offered no clinically meaningful advantage in reducing eye pressure over latanoprost alone. The company said it hired Weinberg Partners as a financial advisor to assist with a strategic review process.

Inotek’s stock subsequently fell to under a $1 from a high of $9.48 on Sept. 26, 2016. The firm went public in February 2015 in a downsized offering that raised $40 million.

In January, the company revealed that trabodenoson failed to achieve its primary endpoint of efficacy in IOP reduction over placebo at all time points in a Phase III trial as a monotherapy.

Inotek describes trabodenoson as a first-in-class, highly selective adenosine mimetic targeting the A1 subreceptor, which lowers IOP by augmenting the eye’s natural function of the trabecular meshwork.

 

 

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Will Comply with FDA Warning Letter

GenSight Receives UK Approval to Start Phase I/II Trial of Gene Therapy for Retinitis Pigmentosa

US FDA Outlines Compounding Policy, Defines Drugs that are ‘Essentially Copies’

Major US Hospitals Plan to Create Generic Drug Company, NYT Reports

Glaukos’ iDose Travoprost Implant Achieves Sustained IOP Reduction in 12-Month Interim Cohort

RXi Plans to Out-License Ophthalmic Segment or Find Development Partner

Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

Iridex Sues Quantel Medical over Patent, Trademark Infringement

pSivida Submits NDA to US FDA for Durasert for Posterior Segment Uveitis

Alimera Sciences Refinances Debt with $40 Million Loan

LENSAR Acquires Mobile Laser Unit of Precision Eye Services

CES 2018 Features Dynafocals Smart Reading Glasses by PH Technical Labs

Novaliq Enrolls First Patient in Phase II Trial for Dry Eye Candidate, Establishes US Subsidiary

Allergan to Eliminate More than Thousand Jobs as Part of Restructuring

Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

Oculis Raises $20.3 Million in Series B Round

Pixium Vision Gets Green Light for US Study of PRIMA Retinal Implant in Atrophic Dry AMD

Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

Coming soon

2018 Ophthalmic Surgical Instruments Report: A Global Market Analysis for 2017 to 2023